Sanjivani Paranteral Ltd

AI
Sanjiv.Parant. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Sanjivani Paranteral Ltd

₹ 180 -0.17%
21 Sep 1:46 p.m.
sanjivani.co.in BSE: 531569
About

Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company[1]

Key Points

Business Overview:[1][2]
SPL is a WHO-GMP, DIGEMID, and
DDA-certified pharmaceutical company specializing in high-quality parenteral and
oral solid formulations. It serves key therapeutic areas including CNS, CVS, antibiotics, urology, anesthetics, gastro enterology, anti-diabetics, anti-fungals, anti-depressants, anti-allergics, muscle relaxants, and vitamin supplements.

Website BSE
  • Market Cap ₹ 220 Cr.
  • Current Price ₹ 180
  • High / Low ₹ 264 / 126
  • Stock P/E 29.6
  • Book Value ₹ 39.3
  • Dividend Yield 0.27 %
  • ROCE 18.0 %
  • ROE 15.7 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Promoter holding is low: 31.6%
  • Company might be capitalizing the interest cost
  • Debtor days have increased from 66.8 to 82.0 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
14.96 12.86 16.44 18.13 17.35 18.18 17.89 15.50 22.06 13.21 23.84
12.99 10.70 14.10 15.28 14.80 15.57 15.25 13.25 18.22 11.64 19.67
Operating Profit 1.97 2.16 2.34 2.85 2.55 2.61 2.64 2.25 3.84 1.57 4.17
OPM % 13.17% 16.80% 14.23% 15.72% 14.70% 14.36% 14.76% 14.52% 17.41% 11.88% 17.49%
0.25 0.05 0.09 0.39 0.31 0.43 0.04 0.16 0.30 0.60 0.15
Interest 0.08 0.09 0.02 0.18 0.19 0.20 0.22 0.05 0.21 0.31 0.35
Depreciation 0.24 0.24 0.13 0.15 0.16 0.18 0.16 0.17 0.23 0.66 0.65
Profit before tax 1.90 1.88 2.28 2.91 2.51 2.66 2.30 2.19 3.70 1.20 3.32
Tax % 13.16% 33.51% 24.56% 21.31% 24.30% 17.29% 24.78% 25.11% 24.86% 55.00% 25.00%
1.65 1.26 1.71 2.30 1.90 2.19 1.73 1.64 2.78 0.55 2.49
EPS in Rs 1.65 1.08 1.46 1.97 1.60 1.84 1.43 1.34 2.26 0.45 2.03
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026 TTM
54.41 70.10 68.67 74.61
46.18 59.76 58.38 62.78
Operating Profit 8.23 10.34 10.29 11.83
OPM % 15.13% 14.75% 14.98% 15.86%
0.52 1.22 0.97 1.21
Interest 0.25 0.59 0.65 0.92
Depreciation 0.93 0.62 1.22 1.71
Profit before tax 7.57 10.35 9.39 10.41
Tax % 18.63% 21.84% 28.75%
6.17 8.09 6.69 7.46
EPS in Rs 5.28 6.81 5.45 6.08
Dividend Payout % 0.00% 7.34% 0.00%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 4%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -8%
Stock Price CAGR
10 Years: 27%
5 Years: 44%
3 Years: 20%
1 Year: -25%
Return on Equity
10 Years: %
5 Years: %
3 Years: 20%
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
Equity Capital 11.68 11.88 12.28
Reserves 16.22 26.11 35.96
0.97 8.14 14.28
14.53 32.07 25.46
Total Liabilities 43.40 78.20 87.98
9.94 20.64 47.34
CWIP 0.00 19.11 1.15
Investments 0.00 0.00 0.73
33.46 38.45 38.76
Total Assets 43.40 78.20 87.98

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
-10.70 12.40 -0.11
-12.21 -21.91 -9.97
23.16 10.46 9.84
Net Cash Flow 0.24 0.94 -0.24
Free Cash Flow -14.00 -17.95 -10.18
CFO/OP -117% 133% 20%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
Debtor Days 31.53 86.85 82.01
Inventory Days 124.70 94.77 91.17
Days Payable 73.56 137.51 30.61
Cash Conversion Cycle 82.67 44.11 142.57
Working Capital Days 35.55 -0.10 45.98
ROCE % 28.46% 17.96%

Insights

In beta
Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Export Revenue Share
% ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Product Category Mix - Injectables Revenue Share
% ・Standalone data
Installed Annual Capacity - Ampoules
million units per annum ・Standalone data
Installed Annual Capacity - Capsules
million units per annum ・Standalone data
Installed Annual Capacity - Tablets
million units per annum ・Standalone data
Region-wise Mix - Latin America Revenue Share
% ・Standalone data
Region-wise Mix - Middle East & Africa Revenue Share
% ・Standalone data
IV Plant (Pune) - Installed Capacity
million bottles per annum ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

2 Recently
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
32.34% 32.34% 27.67% 27.67% 27.67% 27.67% 28.87% 28.87% 31.20% 31.20% 31.26% 31.56%
8.16% 6.01% 9.71% 9.36% 6.26% 6.26% 6.15% 6.15% 6.02% 6.03% 6.03% 5.45%
59.51% 61.65% 62.62% 62.98% 66.08% 66.09% 64.97% 64.98% 62.77% 62.76% 62.71% 62.98%
No. of Shareholders 4,5004,5004,9116,1666,7316,6186,4476,4296,2866,0175,9335,880

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls